

Bibliografía

1. Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for the treatment of schizophrenia and related disorders. *Aust N Z J Psychiatry*. 2005;39(1-2):1-30.
2. Clinical practice guidelines. Treatment of schizophrenia. *Can J Psychiatry*. 2005;50(13 Suppl 1):7S-57S.
3. National Collaborating Centre for Mental Health. Schizophrenia. Full national clinical guideline on core interventions in primary and secondary care. London (United Kingdom): The Royal College of Psychiatrists & The British Psychological Society. National Institut for Clinical Excellence; 2003.
4. Practice guideline for the treatment of patients with schizophrenia [monografía en Internet]. American Psychiatric Association; 2004 [citado 2006]. Disponible en: http://www.psych.org/psych_pract/treatg/pg/SchizPG-Complete-Feb04.pdf
5. Consenso español de expertos para recomendaciones de actuación en el tratamiento de la esquizofrenia. Madrid: Sociedad Española de Psiquiatría; 2000.
6. Strategies therapeutiques a long term dans les psychoses schizophréniques. Paris (France): Fédération Française de Psychiatrie; 1994.
7. Jones C, Cormac I, Silveira da Mota Neto JI, Campbell C. Cognitive behaviour therapy for schizophrenia. *Cochrane Database of Systematic Reviews* 2004, Issue 4. Art. No.: CD000524. DOI: 10.1002/14651858.CD000524.pub2.
8. Tarrier N, Wykes T. Is there evidence that cognitive behaviour therapy is an effective treatment for schizophrenia? A cautious or cautionary tale? *Behav Res Ther*. 2004;42(12):1377-401.
9. Ávila Espada A, Poch Bullich J. Manual de técnicas de psicoterapia. Un enfoque psicoanalítico. Madrid: Siglo Veintiuno de España Editores; 1994.
10. Pekkala E, Merinder L. Psicoeducación para la esquizofrenia (Revisión Cochrane traducida). En: La Biblioteca Cochrane Plus, 2007 Número 2. Oxford: Update Software Ltd. Disponible en: <http://www.update-software.com>. (Traducida de The Cochrane Library, 2007 Issue 2. Chichester, UK: John Wiley & Sons, Ltd.).
11. Barbato A, D'Avanzo B. Family interventions in schizophrenia and related disorders: a critical review of clinical trials. *Acta Psychiatr Scand*. 2000;102(2):81-97.
12. Pitschel-Walz G, Leucht S, Bäuml J, Kissling W, Engel RR. The effect of family interventions on relapse and rehospitalization in schizophrenia--a meta-analysis. *Schizophr Bull*. 2001;27(1):73-92.
13. Butzlaff RL, Hooley JM. Expressed emotion and psychiatric relapse: a meta-analysis. *Arch Gen Psychiatry*. 1998;55(6):547-52.
14. Pharoah F, Mari J, Rathbone J, Wong W. Family intervention for schizophrenia. *Cochrane Database of Systematic Reviews* 2006, Issue 4. Art. No.: CD000088. DOI: 10.1002/14651858.CD000088.pub2.
15. Bustillo JR, Lauriello J, Horan WP, Keith SJ. Actualización del tratamiento psicosocial de la esquizofrenia. *Am J Psychiatr (Ed Esp)*. 2001;4(2):104-16.

16. Huxley NA, Rendall M, Sederer L. Psychosocial treatments in schizophrenia: a review of the past 20 years. *J Nerv Ment Dis.* 2000;188(4):187-201.
17. Sellwood W, Barrowclough C, Tarrrier N, Quinn J, Mainwaring J, Lewis S. Needs-based cognitive-behavioural family intervention for carers of patients suffering from schizophrenia: 12-month follow-up. *Acta Psychiatr Scand.* 2001;104(5):346-55.
18. Barrowclough C, Tarrrier N, Lewis S, Sellwood W, Mainwaring J, Quinn J, et al. Randomised controlled effectiveness trial of a needs-based psychosocial intervention service for carers of people with schizophrenia. *Br J Psychiatry.* 1999;174:505-11.
19. McGurk SR, Twamley EW, Sitzer DI, McHugo GJ, Mueser KT. A meta-analysis of cognitive remediation in schizophrenia. *Am J Psychiatry.* 2007;164(12):1791-802.
20. Velligan DI, Bow-Thomas CC, Huntzinger C, Ritch J, Ledbetter N, Prihoda TJ, et al. Randomized controlled trial of the use of compensatory strategies to enhance adaptive functioning in outpatients with schizophrenia. *Am J Psychiatry.* 2000;157(8):1317-23.
21. Marder SR, Wirshing WC, Mintz J, McKenzie J, Johnston K, Eckman TA, et al. Two-year outcome of social skills training and group psychotherapy for outpatients with schizophrenia. *Am J Psychiatry.* 1996;153(12):1585-92.
22. Killackey EJ, Jackson HJ, Gleeson J, Hickie IB, McGorry PD. Exciting career opportunity beckons! Early intervention and vocational rehabilitation in first-episode psychosis: employing cautious optimism. *Aust N Z J Psychiatry.* 2006;40(11-12):951-62.
23. Twamley EW, Jeste DV, Lehman AF. Vocational rehabilitation in schizophrenia and other psychotic disorders: a literature review and meta-analysis of randomized controlled trials. *J Nerv Ment Dis.* 2003;191(8):515-23.
24. Bond GR, Becker DR, Drake RE, Rapp CA, Meisler N, Lehman AF, et al. Implementing supported employment as an evidence-based practice. *Psychiatr Serv.* 2001;52(3):313-22.
25. Crowther R, Marshall M, Bond G, Huxley P. Vocational rehabilitation for people with severe mental illness. *Cochrane Database of Systematic Reviews* 2001, Issue 2. Art. No.: CD003080. DOI: 10.1002/14651858.CD003080.
26. Lascorz D, Serrats E, Pérez V, Fábregas J, Vegué J. Estudio comparativo coste/eficacia de un dispositivo residencial para enfermos con trastorno mental severo. *Rev Asoc Esp Neuropsiquiatr.* 2009;103(1):191-201.
27. Modelo de Atención a personas con enfermedad mental grave. Documento de consenso. Madrid: IMSERSO. Ministerio de Trabajo y Asuntos Sociales; 2006.
28. McEvoy JP, Scheifler PL, Frances A. Treatment of schizophrenia 1999. The expert consensus guideline series. *J Clin Psychiatry.* 1999;60(Suppl 11):3-80.
29. Malone D, Marriott S, Newton-Howes G, Simmonds S, Tyrer P. Community mental health teams (CMHTs) for people with severe mental illnesses and disordered personality. *Cochrane Database of Systematic Reviews* 2007, Issue 3. Art. No.: CD000270. DOI: 10.1002/14651858.CD000270.pub2.
30. Malm U, Ivarsson B, Allebeck P, Falloon IR. Integrated care in schizophrenia: a 2-year randomized controlled study of two community-based treatment programs. *Acta Psychiatr Scand.* 2003;107(6):415-23.

31. Marshall M, Gray A, Lockwood A, Green R. Case management for people with severe mental disorders. *Cochrane Database of Systematic Reviews* 1998, Issue 2. Art. No.: CD000050. DOI: 10.1002/14651858.CD000050.
32. Mueser KT, Bond GR, Drake RE, Resnick SG. Models of community care for severe mental illness: a review of research on case management. *Schizophr Bull.* 1998;24(1):37-74.
33. Burns T, Catty J, Dash M, Roberts C, Lockwood A, Marshall M. Use of intensive case management to reduce time in hospital in people with severe mental illness: systematic review and meta-regression. *BMJ.* 2007;335(7615):336.
34. American Academy of Child and Adolescent Psychiatry. Practice parameter for the assessment and treatment of children and adolescents with schizophrenia. *J Am Acad Child Adolesc Psychiatry.* 2001;40(7 Suppl):4S-23S.
35. Field MJ, Lohr KN, editores. *Guidelines for Clinical Practice: From development to use.* Washington, DC (US): National Academy Press; 1992.
36. Management of Psychoses [monografía en Internet]. Washington, DC (US): Veterans Health Administration. Department of Veterans Affairs. Health Affairs Department of Defense; May 2004 [citado 2006]. Disponible en: http://www.oqp.med.va.gov/cpg/Psy/Psy_Base.htm
37. Schizophrenia. Singapore: National Government Agency. Ministry of Health; 2003. MOH Clinical Practice Guidelines 2/2003.
38. Ministerio de Salud. Guía clínica primer episodio esquizofrenia. Santiago de Chile (Chile): Minsal; 2005.
39. Miller AL, Hall CS, Buchanan RW, Buckley PF, Chiles JA, Conley RR, et al. The Texas medication algorithm project antipsychotic algorithm for schizophrenia: 2003 update. *J Clin Psychiatry.* 2004;65(4):500-8.
40. Lehman AF, Kreyenbuhl J, Buchanan RW, Dickerson FB, Dixon LB, Goldberg R, et al. The Schizophrenia Patient Outcomes Research Team (PORT): updated treatment recommendations 2003. *Schizophr Bull.* 2004;30(2):193-217.
41. Ehmann T, Yager J, Hanson L. Early psychosis: a review of the treatment literature [monografía en Internet]. Vancouver (Canada): British Columbia Ministry of Children and Family Development; 2004 [citado 2006]. Disponible en: http://www.child-mentalhealth.ubc.ca/documents/publications/Mheccu_EPI_Aug04.pdf
42. International Early Psychosis Association Writing Group. International clinical practice guidelines for early psychosis. *Br J Psychiatry Suppl.* 2005;48(187):S120-4.
43. Lehman AF, Steinwachs DM. Translating research into practice: the Schizophrenia Patient Outcomes Research Team (PORT) treatment recommendations. *Schizophr Bull.* 1998;24(1):1-10.
44. Ey H. *Traité des hallucinations.* Paris (France): Masson; 1973.
45. Kraepelin E. *Introduction a la psychiatrie clinique.* Paris (France): Vigon; 1907.
46. Bleuer E. *Tratado de psiquiatría.* Madrid: Calpe; 1924.
47. American Psychiatric Association. Practice guideline for the treatment of patients with schizophrenia. *Am J Psychiatry.* 1997;154(4 Suppl):1-63.

48. Häfner H, Riecher-Rössler A, Hambrecht M, Maurer K, Meissner S, Schmidtke A, et al. IRAOS: an instrument for the assessment of onset and early course of schizophrenia. *Schizophr Res.* 1992;6:209-23.
49. Huber G, Gross G. The concept of basic symptoms in schizophrenia and schizoaffective psychosis. *Rec Progr Med.* 1989;80:646-52.
50. Yung AR, McGorry PD. The prodromal phase of first episode psychosis: past and current conceptualisations. *Schizo Bulletin.* 1996;22:353-70.
51. Birchwood M, Smith J, Macmillan F, Hogg B, Prasad R, Harvey C, et al. Predicting relapse in schizophrenia: the development and implementation of an early signs monitoring system using patients and families as observers, a preliminary investigation. *Psychol Med.* 1989;19:649-56.
52. Yung AR, Yuen HP, McGorry PD, Phillips LJ, Kelly D, Dell'Olio M, et al. Mapping the onset of psychosis: the comprehensive assessment of at risk mental states. *Austr New Zealand J of Psychiat.* 2005;39(11-12):964-71.
53. McGlashan TH, Zipursky RB, Perkins D, Addington J, Miller TJ, Woods SW, et al. The PRIME North America randomised double-blind clinical trial of olanzapine versus placebo in patients at risk of being prodromally symptomatic for psychosis. I. Study rationale and design. *Schizophr Res.* 2003;61(1):7-18.
54. Yung AR, Phillips LJ, Yuen HP, McGorry PD. Risk factors for psychosis in an ultra high-risk group: psychopathology and clinical features. *Schizophr Res.* 2003;67:131-42.
55. Screening and treatment of adolescents with schizophrenia. The Hague (The Netherlands): Health Council of The Netherlands; 1999. Informe Núm. 1999/08E.
56. Vázquez-Barquero JL, Cuesta Núñez MJ, de la Varga M, Herrera Castañedo S, Gaité L, Arenal A. The Cantabria first episode schizophrenia study: a summary of general findings. *Acta Psychiatr Scand.* 1995;91(3):156-62.
57. Murray RM. Epidemiological evidence concerning the diagnostic status of schizophrenia and bipolar disorder epidemiological [abstract of the XX International Congress on Schizophrenia Research]. *Schizophr Bull.* 2007;33(2):243.
58. Jablensky A, Sartorius N, Ernberg G, Anker M, Korten A, Cooper JE, et al. Schizophrenia: manifestations, incidence and course in different cultures. A World Health Organization ten-country study. *Psychol Med Monogr Suppl.* 1992;20:1-97.
59. Sartorius N, Jablensky A, Korten A, Ernberg G, Anker M, Cooper JE, et al. Early manifestations and first-contact incidence of schizophrenia in different cultures. A preliminary report on the initial evaluation phase of the WHO Collaborative Study on determinants of outcome of severe mental disorders. *Psychol Med.* 1986;16:909-28.
60. McGrath JJ. Myths and plain truths about schizophrenia epidemiology - the NAPE lecture 2004. *Acta Psychiatr Scand.* 2005;111(1):4-11.
61. McGrath JJ. Variations in the incidence of schizophrenia: data versus dogma. *Schizophr Bull.* 2006;32(1):195-7.
62. McGrath JJ, Saha S, Welham J, El Saadi O, MacCauley C, Chant D. A systematic review of the incidence of schizophrenia: the distribution of rates and the influence of sex, urbanicity, migrant status and methodology. *BMC Med.* 2004;2:13.

63. Kirkbride JB, Fearon P, Morgan C, Dazzan P, Morgan K, Tarrant J, et al. Heterogeneity in incidence rates of schizophrenia and other psychotic syndromes - Findings from the 3 center AESOP study. *Arch Gen Psychiatry*. 2006;63(3):250-8.
64. Saha S, Chant D, Welham J, McGrath JJ. A systematic review of the prevalence of schizophrenia. *PLoS Med*. 2005;2(5):413-33.
65. Baldwin P, Browne D, Scully PJ, Quinn JF, Morgan MG, Kinsella A, et al. Epidemiology of first-episode psychosis: illustrating the challenges across diagnostic boundaries through the Cavan-Monaghan study at 8 years. *Schizophr Bull*. 2005;31(3):624-38.
66. Auquier P, Lancon C, Rouillon F, Lader M, Holmes C. Mortality in schizophrenia. *Pharmacoeconomol Drug Saf*. 2006;15(12):873-9.
67. Othmer E, Othmer SC. DSM-IV-TR. La entrevista clínica. Tomo I. Fundamentos. Barcelona: Editorial Masson; 2002.
68. Clasificación de trastornos mentales CIE 10. Criterios de la OMS (Clasificación Estadística Internacional de Enfermedades y otros Problemas de Salud). Disponible en: <http://www.psicoadactiva.com/cie10/cie1.htm>
69. Chinchilla Moreno A. Guía terapéutica de las esquizofrenias. Barcelona: Editorial Masson; 2000.
70. Consenso español sobre evaluación y tratamiento de la esquizofrenia. Madrid: Sociedad Española de Psiquiatría; 1998.
71. Falloon IR, Montero I, Sungur M, Mastroeni A, Malm U, Economou M, et al. Implementation of evidence-based treatment for schizophrenic disorders: two-year outcome of an international field trial of optimal treatment. *World Psychiatry*. 2004;3(2):104-9.
72. McGorry P, Parkville V, Killackey E, Elkins K, Lambert M. Summary Australian and New Zealand clinical practice guideline for the treatment of schizophrenia (2003). *Australas Psychiatry*. 2003;11(2):136-47.
73. GPT 1. Guía de prescripción terapéutica. Información de medicamentos autorizados en España. Barcelona: Agencia española de medicamentos y productos sanitarios. Pharma Editores SL; 2006.
74. Baldessarini RJ, Cohen BM, Teicher MH. Significance of neuroleptic dose and plasma level in the pharmacological treatment of psychoses. *Arch Gen Psychiatry*. 1988;45(1):79-91.
75. Falkai P, Wobrock T, Lieberman J, Glenthøj B, Gattaz WF, Moller HJ. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, part 2: long-term treatment of schizophrenia. *World J Biol Psychiatry*. 2006;7(1):5-40.
76. Falkai P, Wobrock T, Lieberman J, Glenthøj B, Gattaz WF, Moller HJ. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, part 1: acute treatment of schizophrenia. *World J Biol Psychiatry*. 2005;6(3):132-91.
77. Soler P, Gascón J. RTM III. Recomendaciones terapéuticas en los trastornos mentales. Comité de consenso de Catalunya en terapéutica de los trastornos mentales. 3a ed. Barcelona: Ars Medica; 2005.
78. Chinchilla Moreno A. Las esquizofrenias: sus hechos y valores clínicos terapéuticos. Barcelona: Elsevier Masson; 2007.

79. Casey DE. Neuroleptic drug-induced extrapyramidal syndromes and tardive dyskinesia. *Schizophr Res.* 1991;4(2):109-20.
80. Ayd FJ Jr. A survey of drug-induced extrapyramidal reactions. *JAMA.* 1961;175:1054-60.
81. Chakos MH, Mayerhoff DI, Loebel AD, Alvir JM, Lieberman JA. Incidence and correlates of acute extrapyramidal symptoms in first episode of schizophrenia. *Psychopharmacol Bull.* 1992;28(1):81-6.
82. Leucht S. Amisulpride a selective dopamine antagonist and atypical antipsychotic: results of a meta-analysis of randomized controlled trials. *Int J Neuropsychopharmacol.* 2004;7 Suppl 1:S15-20.
83. McGavin JK, Goa KL. Aripiprazole. *CNS Drugs.* 2002;16(11):779-86.
84. Travis MJ, Burns T, Dursun S, Fahy T, Frangou S, Gray R, et al. Aripiprazole in schizophrenia: consensus guidelines. *Int J Clin Pract.* 2005;59(4):485-95.
85. Leucht S, Corves C, Arbter D, Engel RR, Li C, Davis JM. Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. *Lancet.* 2009;373(9657):31-41.
86. Kane J, Honigfeld G, Singer J, Meltzer H. Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine. *Arch Gen Psychiatry.* 1988;45(9):789-96.
87. Bagnall AM, Jones L, Ginnelly L, Lewis R, Glanville J, Gilbody S, et al. A systematic review of atypical antipsychotic drugs in schizophrenia. *Health Technol Assess* 2003;7(13):1-193.
88. Kasper S, Müller-Spahn F. Review of quetiapine and its clinical applications in schizophrenia. *Expert Opin Pharmacother.* 2000;1(4):783-801.
89. Bondolfi G, Dufour H, Patris M, May JP, Billeter U, Eap CB, et al. Risperidone versus clozapine in treatment-resistant chronic schizophrenia: a randomized double-blind study. The Risperidone Study Group. *Am J Psychiatry.* 1998;155(4):499-504.
90. Aranza J, García E, Sádaba B, Muñoz M. Ziprasidona. *Farmacología práctica. Actas Esp Psiquiatr.* 2002;30(2):1-9.
91. Villegas I, López Román F, Martínez González A, Villegas J. Obesidad y síndrome metabólico en pacientes con esquizofrenia. *Psiqu Biol.* 2005;12(2):39-45.
92. Grundy SM, Cleeman JI, Merz CN, Brewer HB Jr, Clark LT, Hunninghake DB, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. *Arterioscler Thromb Vasc Biol.* 2004;24(8):e149-61.
93. Bergman RN, Ader M. Atypical antipsychotics and glucose homeostasis. *J Clin Psychiatry.* 2005;66(4):504-14.
94. Lambert TJ, Chapman LH. Diabetes, psychotic disorders and antipsychotic therapy: a consensus statement. *Med J Aust.* 2004;181(10):544-8.
95. Ramaswamy K, Masand PS, Nasrallah HA. Do certain atypical antipsychotics increase the risk of diabetes? A critical review of 17 pharmacoepidemiologic studies. *Ann Clin Psychiatry.* 2006;18(3):183-94.

96. Jin H, Meyer JM, Jeste DV. Atypical antipsychotics and glucose dysregulation: a systematic review. *Schizophr Res.* 2004;71(2-3):195-212.
97. Bellantuono C, Tentoni L, Donda P. Antipsychotic drugs and risk of type 2 diabetes: an evidence-based approach. *Hum Psychopharmacol.* 2004;19(8):549-58.
98. Philippe A, Vaiva G, Casadebaig F. Data on diabetes from the French cohort study in schizophrenia. *Eur Psychiatry.* 2005;20 Suppl 4:S340-4.
99. Cavazzoni P, Mukhopadhyay N, Carlson C, Breier A, Buse J. Retrospective analysis of risk factors in patients with treatment-emergent diabetes during clinical trials of antipsychotic medications. *Br J Psychiatry Suppl.* 2004;47:S94-101.
100. Bushe C, Leonard B. Association between atypical antipsychotic agents and type 2 diabetes: review of prospective clinical data. *Br J Psychiatry Suppl.* 2004;47:S87-93.
101. Marder SR, Essock SM, Miller AL, Buchanan RW, Casey DE, Davis JM, et al. Physical health monitoring of patients with schizophrenia. *Am J Psychiatry.* 2004;161(8):1334-49.
102. Perfil de toxicidad de los antipsicóticos atípicos. *Butlletí Groc (Fundació Institut Català de Farmacologia de la Universitat Autònoma de Barcelona).* 2002;15(1). Disponible en: <http://www.icf.uab.es/informacion/boletines/bg/bg151.02e.pdf>
103. Ray WA, Chung CP, Murray KT, Hall K, Stein CM. Atypical antipsychotic drugs and the risk of sudden cardiac death. *N Engl J Med.* 2009;360(3):225-35.
104. Jackson CW, Markowitz JS, Brewerton TD. Delirium associated with clozapine and benzodiazepine combinations. *Ann Clin Psychiatry.* 1995;7(3):139-41.
105. Hatta K, Takahashi T, Nakamura H, Fujii S, Yamashiro H, Asukai N, et al. Prolonged upper airway instability in the parenteral use of benzodiazepine with levomepromazine. *J Clin Psychopharmacol.* 2000;20(1):99-101.
106. APA Practice Guideline Development Process [monografía en Internet]. Arlington, VA (US): The American Psychiatric Association (APA); 2004. Disponible en: <http://www.psych.org>
107. Emsley RA. Risperidone in the treatment of first-episode psychotic patients: a double-blind multicenter study. Risperidone Working Group. *Schizophr Bull.* 1999;25(4):721-9.
108. Fagerlund B, Mackeprang T, Gade A, Glenthøj BY. Effects of low-dose risperidone and low-dose zuclopenthixol on cognitive functions in first-episode drug-naive schizophrenic patients. *CNS Spectr.* 2004;9(5):364-74.
109. Sanger TM, Lieberman JA, Tohen M, Grundy S, Beasley C Jr, Tollefson GD. Olanzapine versus haloperidol treatment in first-episode psychosis. *Am J Psychiatry.* 1999;156(1):79-87.
110. Lieberman JA, Phillips M, Gu H, Stroup S, Zhang P, Kong L, et al. Atypical and conventional antipsychotic drugs in treatment-naive first-episode schizophrenia: a 52-week randomized trial of clozapine vs chlorpromazine. *Neuropsychopharmacology.* 2003;28(5):995-1003.
111. Bobes J, Gibert J, Ciudad A, Álvarez E, Canas F, Carrasco JL, et al. Safety and effectiveness of olanzapine versus conventional antipsychotics in the acute treatment of

- first-episode schizophrenic inpatients. *Prog Neuropsychopharmacol Biol Psychiatry*. 2003;27(3):473-81.
112. Lieberman JA, Tollefson G, Tohen M, Green AI, Gur RE, Kahn R, et al. Comparative efficacy and safety of atypical and conventional antipsychotic drugs in first-episode psychosis: a randomized, double-blind trial of olanzapine versus haloperidol. *Am J Psychiatry*. 2003;160(8):1396-404.
 113. van BJ, Tijssen J, Dingemans P, Gersons B, Linszen D. Symptom response and side-effects of olanzapine and risperidone in young adults with recent onset schizophrenia. *Int Clin Psychopharmacol*. 2003;18(6):341-6.
 114. Van Brummen HJ, Bruinse HW, Van der Bom JG, Heintz AP, Van der Vaart CH. How do the prevalences of urogenital symptoms change during pregnancy? *Neurourol Urodyn*. 2006;25(2):135-9.
 115. National Collaborating Centre for Mental Health. Schizophrenia. Core interventions in the treatment and management of schizophrenia in primary and secondary care. London (United Kingdom): National Institute for Clinical Excellence; 2002. Clinical Guideline 1.
 116. Moore TA, Covell NH, Essock SM, Miller AL. Real-world antipsychotic treatment practices. *Psychiatr Clin North Am*. 2007;30(3):401-16.
 117. Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. *N Engl J Med*. 2005;353(12):1209-23.
 118. Keefe RS, Bilder RM, Davis SM, Harvey PD, Palmer BW, Gold JM, et al. Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE Trial. *Arch Gen Psychiatry*. 2007;64(6):633-47.
 119. Jones PB, Barnes TR, Davies L, Dunn G, Lloyd H, Hayhurst KP, et al. Randomized controlled trial of the effect on quality of life of second- vs first-generation antipsychotic drugs in schizophrenia: cost utility of the latest antipsychotic drugs in schizophrenia study (CUtLASS 1). *Arch Gen Psychiatry*. 2006;63(10):1079-87.
 120. Lewis S, Lieberman J. CATIE and CUtLASS: can we handle the truth? *Br J Psychiatry*. 2008;192(3):161-3.
 121. Schooler N, Rabinowitz J, Davidson M, Emsley R, Harvey PD, Kopala L, et al. Risperidone and haloperidol in first-episode psychosis: a long-term randomized trial. *Am J Psychiatry*. 2005;162(5):947-53.
 122. McEvoy JP, Lieberman JA, Perkins DO, Hamer RM, Gu H, Lazarus A, et al. Efficacy and tolerability of olanzapine, quetiapine, and risperidone in the treatment of early psychosis: a randomized, double-blind 52-week comparison. *Am J Psychiatry*. 2007;164(7):1050-60.
 123. Schooler NR. The efficacy of antipsychotic drugs and family therapies in the maintenance treatment of schizophrenia. *J Clin Psychopharmacol*. 1986;6(1 Suppl):11S-19S.
 124. Opjordsmoen S, Melle I, Friis S, Haahr U, Johannessen JO, Tor K, et al. Stability of medication in early psychosis: a comparison between second-generation and low-dose first-generation antipsychotics. *Early Interv Psychiatry*. 2009;3(1):58-65.
 125. Rojo Rodés JE, Vallejo Ruiloba J. *Terapia electroconvulsiva*. Barcelona: Masson-Salvat; 1994.

126. Tharyan P, Adams CE. Electroconvulsive therapy for schizophrenia. Cochrane Database of Systematic Reviews 2005, Issue 2. Art. No.: CD000076. DOI: 10.1002/14651858.CD000076.pub2.
127. Painuly N, Chakrabarti S. Combined use of electroconvulsive therapy and antipsychotics in schizophrenia: the Indian evidence. A review and a meta-analysis. *J ECT*. 2006;22(1):59-66.
128. Bertolín Guillén JM, Sáez AC, Hernández de Pablo ME, Peiró MS. Eficacia de la terapia electroconvulsiva: revisión sistemática de las evidencias científicas. *Actas Esp Psiquiatr*. 2004;32(3):153-65.
129. La psicoterapia a la xarxa pública de Salut Mental y Adiccions [document d'ús intern]. Barcelona; 2007.
130. Lehman AF, Steinwachs DM. Evidence-based psychosocial treatment practices in schizophrenia: lessons from the patient outcomes research team (PORT) project. *J Am Acad Psychoanal Dyn Psychiatry*. 2003;31(1):141-54.
131. Fenton WS. Evolving perspectives on individual psychotherapy for schizophrenia. *Schizophr Bull*. 2000;26(1):47-72.
132. Gisbert C, coordinación. Rehabilitación psicosocial del trastorno mental severo. Situación actual y recomendaciones. Madrid: Asociación Española de Neuropsiquiatría (AEN); 2002. Cuadernos Técnico Núm. 6.
133. Kanas N. Group therapy with schizophrenics: a review of controlled studies. *Int J Group Psychother*. 1986;36(3):339-60.
134. Gaudio BA. Is symptomatic improvement in clinical trials of cognitive-behavioral therapy for psychosis clinically significant? *J Psychiatr Pract*. 2006;12(1):11-23.
135. Zimmermann G, Favrod J, Trieu VH, Pomini V. The effect of cognitive behavioral treatment on the positive symptoms of schizophrenia spectrum disorders: a meta-analysis. *Schizophr Res*. 2005;77(1):1-9.
136. Jackson C. Promoting personal recovery from psychosis: A randomised controlled trial in first episode schizophrenia [ensayo clínico finalizado]. Birmingham (United Kingdom): North Birmingham Mental Health NHS Trust; 2003. Disponible en: <http://www.controlled-trials.com/isrctn/pf/43585723>
137. Garety PA, Craig TK, Dunn G, Fornells-Ambrojo M, Colbert S, Rahaman N, et al. Specialised care for early psychosis: symptoms, social functioning and patient satisfaction: randomised controlled trial. *Br J Psychiatry*. 2006;188:37-45.
138. Marshall M, Rathbone J. Early Intervention for psychosis. Cochrane Database of Systematic Reviews 2006, Issue 4. Art. No.: CD004718. DOI: 10.1002/14651858.CD004718.pub2.
139. Jackson H, McGorry P, Edwards J, Hulbert C, Henry L, Harrigan S, et al. A controlled trial of cognitively oriented psychotherapy for early psychosis (COPE) with four-year follow-up readmission data. *Psychol Med*. 2005;35(9):1295-306.
140. Pfammatter M, Junghan UM, Brenner HD. Efficacy of psychological therapy in schizophrenia: conclusions from meta-analyses. *Schizophr Bull*. 2006;32 Suppl 1:S64-80.

141. Crawford-Walker CJ, King A, Chan S. Distraction techniques for schizophrenia. Cochrane Database of Systematic Reviews 2005, Issue 1. Art. No.: CD004717. DOI: 10.1002/14651858.CD004717.pub2.
142. Penn DL, Waldheter EJ, Perkins DO, Mueser KT, Lieberman JA. Psychosocial treatment for first-episode psychosis: a research update. *Am J Psychiatry*. 2005;162(12):2220-32.
143. Lawrence R, Bradshaw T, Mairs H. Group cognitive behavioural therapy for schizophrenia: a systematic review of the literature. *J Psychiatr Ment Health Nurs*. 2006;13(6):673-81.
144. Grawe RW, Falloon IR, Widen JH, Skogvoll E. Two years of continued early treatment for recent-onset schizophrenia: a randomised controlled study. *Acta Psychiatr Scand*. 2006;114(5):328-36.
145. Dickerson FB, Lehman AF. Evidence-based psychotherapy for schizophrenia. *J Nerv Ment Dis*. 2006;194(1):3-9.
146. Penn DL, Mueser KT, Tarrrier N, Gloege A, Cather C, Serrano D, et al. Supportive therapy for schizophrenia: possible mechanisms and implications for adjunctive psychosocial treatments. *Schizophr Bull*. 2004;30(1):101-12.
147. Buckley LA, Pettit TA, Adams CE. Supportive therapy for schizophrenia. Cochrane Database of Systematic Reviews 2007, Issue 3. Art. No.: CD004716. DOI: 10.1002/14651858.CD004716.pub3.
148. Malmberg L, Fenton M. Individual psychodynamic psychotherapy and psychoanalysis for schizophrenia and severe mental illness. Cochrane Database of Systematic Reviews 2001, Issue 3. Art. No.: CD001360. DOI: 10.1002/14651858.CD001360.
149. Gottdiener W, Haslam N. The benefits of individual psychotherapy for schizophrenic patients: a meta-analytical review. *Ethical Hum Sci Serv*. 2002;4:163-87.
150. Gabbard GO, Gunderson JG, Fonagy P. The place of psychoanalytic treatments within psychiatry. *Arch Gen Psychiatry*. 2002;59(6):505-10.
151. Valbak K, Koster A, Larsen KA, Nielsen JR, Norrie B. The Danish national multicenter schizophrenia project: assessment of psychotic patients for dynamic psychotherapy (APPP). *Nord J Psychiatry*. 2003;57(5):333-8.
152. Rosenbaum B, Valbak K, Harder S, Knudsen P, Koster A, Lajer M, et al. The Danish National Schizophrenia Project: prospective, comparative longitudinal treatment study of first-episode psychosis. *Br J Psychiatry*. 2005;186:394-9.
153. Pitschel-Walz G, Bäuml J, Bender W, Engel RR, Wagner M, Kissling W. Psychoeducation and compliance in the treatment of schizophrenia: results of the Munich Psycho-sis Information Project Study. *J Clin Psychiatry*. 2006;67(3):443-52.
154. Brown G, Carstairs JM, Topping GG. The post-hospital adjustment of chronic mental patients. *Lancet*. 1958; 2(7048):685-8.
155. Pharoah F, Mari J, Rathbone J, Wong W. Intervención familiar para la esquizofrenia (Revisión Cochrane traducida). En: La Biblioteca Cochrane Plus, 2007 Número 2. Oxford: Update Software Ltd. Disponible en: <http://www.update-software.com>. (Traducida de The Cochrane Library, 2007 Issue 2. Chichester, UK: John Wiley & Sons, Ltd.).

156. McFarlane WR, Dixon L, Lukens E, Lucksted A. Family psychoeducation and schizophrenia: a review of the literature. *J Marital Fam Ther.* 2003;29(2):223-45.
157. Jeppesen P, Petersen L, Thorup A, Abel M, Ehlerschlger J, Christensen T, et al. Integrated treatment of first-episode: effect of treatment on family burden. *Br J Psychiatry.* 2005;187:S85-90.
158. Pickett-Schenk SA, Cook JA, Steigman P, Lippincott R, Bennett C, Grey DD. Psychological well-being and relationship outcomes in a randomized study of family-led education. *Arch Gen Psychiatry.* 2006;63(9):1043-50.
159. Panades R. La rehabilitación neuropsicológica del paciente esquizofrénico [tesis doctoral]. Barcelona: Universitat de Barcelona; 2002.
160. Lewis R. Should cognitive deficit be a diagnostic criterion for schizophrenia? *J Psychiatry Neurosci.* 2004;29(2):102-13.
161. Hayes RL, McGrath JJ. Cognitive rehabilitation for people with schizophrenia and related conditions. *Cochrane Database of Systematic Reviews* 2000, Issue 3. Art. No.: CD000968. DOI: 10.1002/14651858.CD000968.
162. Krabbendam L, Aleman A. Cognitive rehabilitation in schizophrenia: a quantitative analysis of controlled studies. *Psychopharmacology (Berl).* 2003;169(3-4):376-82.
163. Kurtz MM. Symptoms versus neurocognitive skills as correlates of everyday functioning in severe mental illness. *Expert Rev Neurother.* 2006;6(1):47-56.
164. Johnson-Selfridge M, Zalewski C. Moderator variables of executive functioning in schizophrenia: meta-analytic findings. *Schizophr Bull.* 2001;27(2):305-16.
165. Kurtz MM, Moberg PJ, Gur RC, Gur RE. Approaches to cognitive remediation of neuropsychological deficits in schizophrenia: a review and meta-analysis. *Neuropsychol Rev.* 2001;11(4):197-210.
166. Nieuwenstein MR, Aleman A, de Haan EH. Relationship between symptom dimensions and neurocognitive functioning in schizophrenia: a meta-analysis of WCST and CPT studies. Wisconsin card sorting test. Continuous performance test. *J Psychiatr Res.* 2001;35(2):119-25.
167. Suslow T, Schonauer K, Arolt V. Attention training in the cognitive rehabilitation of schizophrenic patients: a review of efficacy studies. *Acta Psychiatr Scand.* 2001;103(1):15-23.
168. Roder V, Mueller DR, Mueser KT, Brenner HD. Integrated psychological therapy (IPT) for schizophrenia: is it effective? *Schizophr Bull.* 2006;32 Suppl 1:S81-93.
169. Vishnu Gopal Y, Variend H. First-episode schizophrenia: review of cognitive deficits and cognitive remediation. *Adv psych treat.* 2005;11:38-44.
170. Ponte Velón J, Goienetxea Laiuno B, Serna Herrán I, Picaza Ereño U, Elortegui Cayero I, Sánchez N, et al. Función cognitiva en primeros episodios psicóticos: estudio de las habilidades ejecutivas y resolución de problemas [póster]. En: VII Congreso Nacional de Psiquiatría: Psicopatología en tiempos de la Neurociencia. Palma de Mallorca; 21-25 octubre 2003.
171. Bellack AS, Mueser KT. Psychosocial treatment for schizophrenia. *Schizophr Bull.* 1993;19(2):317-36.

172. Penn DL, Mueser KT. Research update on the psychosocial treatment of schizophrenia. *Am J Psychiatry*. 1996;153(5):607-17.
173. Liberman RP, Wallace CJ, Blackwell G, Kopelowicz A, Vaccaro JV, Mintz J. Skills training versus psychosocial occupational therapy for persons with persistent schizophrenia. *Am J Psychiatry*. 1998;155(8):1087-91.
174. Spaulding WD, Reed D, Sullivan M, Richardson C, Weiler M. Effects of cognitive treatment in psychiatric rehabilitation. *Schizophr Bull*. 1999;25(4):657-76.
175. Tungpunkom P, Nicol M. Life skills programmes for chronic mental illnesses. *Cochrane Database of Systematic Reviews* 2008, Issue 2. Art. No.: CD000381. DOI: 10.1002/14651858.CD000381.pub2.
176. Ruddy R, Milnes D. Art therapy for schizophrenia or schizophrenia-like illnesses. *Cochrane Database of Systematic Reviews* 2005, Issue 4. Art. No.: CD003728. DOI: 10.1002/14651858.CD003728.pub2.
177. Gold C, Heldal TO, Dahle T, Wigram T. Music therapy for schizophrenia or schizophrenia-like illnesses. *Cochrane Database of Systematic Reviews* 2005, Issue 2. Art. No.: CD004025. DOI: 10.1002/14651858.CD004025.pub2.
178. National Collaborating Centre for Mental Health. Schizophrenia. Core interventions in the treatment and management of schizophrenia in primary and secondary care (update). Draft for consultation [documento provisional]. London (United Kingdom): National Institute for Clinical Excellence; September 2008.
179. Trastorno mental grave: proceso asistencial integrado. Sevilla: Consejería de Salud; 2006.
180. Drake RE, Mueser KT, Torrey WC, Miller AL, Lehman AF, Bond GR, et al. Evidence-based treatment of schizophrenia. *Curr Psychiatry Rep*. 2000;2(5):393-7.
181. Crowther R, Marshall M, Bond G, Huxley P. Rehabilitación vocacional para personas con enfermedades mentales graves (Revisión Cochrane traducida). En: *La Biblioteca Cochrane Plus*, 2008 Número 1. Oxford: Update Software Ltd. Disponible en: <http://www.update-software.com>. (Traducida de The Cochrane Library, 2008 Issue 1. Chichester, UK: John Wiley & Sons, Ltd.).
182. Michon HW, Van WJ, Kroon H, Schene AH. Person-related predictors of employment outcomes after participation in psychiatric vocational rehabilitation programmes--a systematic review. *Soc Psychiatry Psychiatr Epidemiol*. 2005;40(5):408-16.
183. Bond GR. Supported employment: evidence for an evidence-based practice. *Psychiatr Rehabil J*. 2004;27(4):345-59.
184. Rinaldi M, McNeil K, Firn M, Koleti M, Perkins R. What are the benefits of evidence-based supported employment for patients with first-episode psychosis. *Psychiatr Bull*. 2004;28:281-4.
185. López M, Laviana M, García-Cubillana P, Fernández L, Moreno B, López A. Evaluación del programa residencial para personas con trastorno mental severo en Andalucía (V): actitudes y grado de satisfacción de los residentes. *Rehabil psicosoc*. 2005;2(2):56-63.
186. Chilvers R, Macdonald GM, Hayes AA. Supported housing for people with severe mental disorders. *Cochrane Database of Systematic Reviews* 2006, Issue 4. Art. No.: CD000453. DOI: 10.1002/14651858.CD000453.pub2.

187. Durbin J, Goering P, Cochrane J, MacFarlane D, Sheldon T. Needs-based planning for persons with schizophrenia residing in board-and-care homes. *Schizophr Bull.* 2004;30(1):123-32.
188. Burns T. *Community mental health teams. A guide to current practices.* New York, NY (US): Oxford University Press; 2005.
189. Care services improvement partnership. *Reviewing the care program approach 2006. A consultation document.* London (United Kingdom): Department of Health; 2006.
190. Burns T, Fioritti A, Holloway F, Malm U, Rossler W. Case management and assertive community treatment in Europe. *Psychiatr Serv.* 2001;52(5):631-6.
191. Thorup A, Petersen L, Jeppesen P, Ohlenschlaeger J, Christensen T, Krarup G, et al. Integrated treatment ameliorates negative symptoms in first episode psychosis--results from the Danish OPUS trial. *Schizophr Res.* 2005;79(1):95-105.
192. Killaspy H, Bebbington P, Blizard R, Johnson S, Nolan F, Pilling S, et al. The REACT study: randomised evaluation of assertive community treatment in north London. *BMJ.* 2006;332(7545):815-20.
193. Commander M, Sashidharan S, Rana T, Ratnayake T. North Birmingham assertive outreach evaluation. Patient characteristics and clinical outcomes. *Soc Psychiatry Psychiatr Epidemiol.* 2005;40(12):988-93.
194. Marshall M, Lockwood A. Assertive community treatment for people with severe mental disorders. *Cochrane Database of Systematic Reviews* 1998, Issue 2. Art. No.: CD001089. DOI: 10.1002/14651858.CD001089.
195. Pla de Serveis Individualitzats (PSI). Barcelona: Consell Assessor sobre Assistència Psiquiàtrica i Salut Mental. CatSalut. Servei Català de la Salut; 2003.
196. Martin G, Costello H, Leese M, Slade M, Bouras N, Higgins S, et al. An exploratory study of assertive community treatment for people with intellectual disability and psychiatric disorders: conceptual, clinical, and service issues. *J Intellect Disabil Res.* 2005;49(Pt 7):516-24.
197. Cosden M, Ellens J, Schnell J, Yamini-Diouf Y. Efficacy of a mental health treatment court with assertive community treatment. *Behav Sci Law.* 2005;23(2):199-214.
198. Yang J, Law S, Chow W, Andermann L, Steinberg R, Sadavoy J. Best practices: assertive community treatment for persons with severe and persistent mental illness in ethnic minority groups. *Psychiatr Serv.* 2005;56(9):1053-5.
199. Carney CP, Jones L, Woolson RF. Medical comorbidity in women and men with schizophrenia: a population-based controlled study. *J Gen Intern Med.* 2006;21(11):1133-7.
200. Kelly M, Lamah M. Evaluating the accuracy of data entry in a regional colorectal cancer database: implications for national audit. *Colorectal Dis.* 2007;9(4):337-9.
201. American Diabetes Association, American Psychiatric Association, American Association of Clinical Endocrinologists, North American Association for the Study of Obesity. Consensus development conference on antipsychotic drugs and obesity and diabetes. *J Clin Psychiatry.* 2004;65(2):267-72.
202. Consenso sobre promoción de la salud mental, prevención del trastorno mental y disminución del estigma de la Asociación Española de Neuropsiquiatría. Madrid: Asociación Española de Neuropsiquiatría; 2007.

203. Enfermedad mental: análisis de las actitudes de rechazo social y estigmatización que sufren las personas con enfermedad mental. Madrid: Consejería de Asuntos Sociales de la Comunidad de Madrid; 2006.
204. Corrigan P, Thompson V, Lambert D, Sangster Y, Noel JG, Campbell J. Perceptions of discrimination among persons with serious mental illness. *Psychiatr Serv.* 2003;54(8):1105-10.
205. Berzins KM, Petch A, Atkinson JM. Prevalence and experience of harassment of people with mental health problems living in the community. *Br J Psychiatry.* 2003;183:526-33.
206. Edwards J, McGorry P. La intervención precoz en la psicosis: Guía para la creación de servicios de intervención precoz en la psicosis. Madrid: Fundación para el tratamiento de la esquizofrenia y otras psicosis; 2004.
207. Birchwood M, Todd P, Jackson C. Early intervention in psychosis. The critical period hypothesis. *Br J Psychiatry Suppl.* 1998;172(33):53-9.
208. McGorry PD, Yung AR, Phillips LJ. The “close-in” or ultra high-risk model: a safe and effective strategy for research and clinical intervention in prepsychotic mental disorder. *Schizophr Bull.* 2003;29(4):771-90.
209. McGorry PD, Yung AR, Phillips LJ, Yuen HP, Francey S, Cosgrave EM, et al. Randomized controlled trial of interventions designed to reduce the risk of progression to first-episode psychosis in a clinical sample with subthreshold symptoms. *Arch Gen Psychiatry.* 2002;59(10):921-8.
210. Yung AR, McGorry PD. The prodromal phase of first-episode psychosis: past and current conceptualizations. *Schizophr Bull.* 1996;22(2):353-70.
211. Yung AR, McGorry PD, McFarlane CA, Jackson HJ, Patton GC, Rakkar A. Monitoring and care of young people at incipient risk of psychosis. *Schizophr Bull.* 1996;22(2):283-303.
212. McGlashan TH. Duration of untreated psychosis in first-episode schizophrenia: marker or determinant of course? *Biol Psychiatry.* 1999;46(7):899-907.
213. Johannessen J, Martindale B, Culberg J. Evolución de las psicosis. Barcelona: Herder; 2008.
214. Larsen TK, Friis S, Haahr U, Joa I, Johannessen JO, Melle I, et al. Early detection and intervention in first-episode schizophrenia: a critical review. *Acta Psychiatr Scand.* 2001;103(5):323-34.
215. Ehmann T, Hanson L. Early Psychosis. A care guide. Vancouver (Canada): Mental Health Evaluation & Community Consultation Unit. University of British Columbia; 2002.
216. Olsen KA, Rosenbaum B. Prospective investigations of the prodromal state of schizophrenia: review of studies. *Acta Psychiatr Scand.* 2006;113(4):247-72.
217. Bechdolf A, Phillips LJ, Francey SM, Leicester S, Morrison AP, Veith V, et al. Recent approaches to psychological interventions for people at risk of psychosis. *Eur Arch Psychiatry Clin Neurosci.* 2006;256(3):159-73.
218. Broome MR, Woolley JB, Johns LC, Valmaggia LR, Tabraham P, Gafoor R, et al. Outreach and support in south London (OASIS): implementation of a clinical service for prodromal psychosis and the at risk mental state. *Eur Psychiatry.* 2005;20(5-6):372-8.

219. Yung AR, Phillips LJ, Yuen HP, McGorry PD. Risk factors for psychosis in an ultra high-risk group: psychopathology and clinical features. *Schizophr Res.* 2004;67(2-3):131-42.
220. Nordentoft M, Thorup A, Petersen L, Ohlenschlaeger J, Melau M, Christensen TO, et al. Transition rates from schizotypal disorder to psychotic disorder for first-contact patients included in the OPUS trial. A randomized clinical trial of integrated treatment and standard treatment. *Schizophr Res.* 2006;83(1):29-40.
221. Phillips LJ, Yung AR, Yuen HP, Pantelis C, McGorry PD. Prediction and prevention of transition to psychosis in young people at incipient risk for schizophrenia. *Am J Med Genet.* 2002;114(8):929-37.
222. Bertolote J, McGorry P. Early intervention and recovery for young people with early psychosis: consensus statement. *Br J Psychiatry Suppl.* 2005;48:s116-9.
223. Singh SP, Grange T. Measuring pathways to care in first-episode psychosis: a systematic review. *Schizophr Res.* 2006;81(1):75-82.
224. Larsen TK, Melle I, Auestad B, Friis S, Haahr U, Johannessen JO, et al. Early detection of first-episode psychosis: the effect on 1-year outcome. *Schizophr Bull.* 2006;32(4):758-64.
225. Perkins DO, Gu H, Boteva K, Lieberman JA. Relationship between duration of untreated psychosis and outcome in first-episode schizophrenia: a critical review and meta-analysis. *Am J Psychiatry.* 2005;162(10):1785-804.
226. Kahn RS, Fleischhacker WW, Boter H, Davidson M, Vergouwe Y, Keet IP, et al. Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial. *Lancet.* 2008;371(9618):1085-97.
227. Tarrier N, Lewis S, Haddock G, Bentall R, Drake R, Kinderman P, et al. Cognitive-behavioural therapy in first-episode and early schizophrenia. 18-month follow-up of a randomised controlled trial. *Br J Psychiatry.* 2004;184:231-9.
228. McGlashan TH, Johannessen JO. Early detection and intervention with schizophrenia: rationale. *Schizophr Bull.* 1996;22(2):201-22.
229. Eckman TA, Wirshing WC, Marder SR, Liberman RP, Johnston-Cronk K, Zimmermann K, et al. Technique for training schizophrenic patients in illness self-management: a controlled trial. *Am J Psychiatry.* 1992;149(11):1549-55.
230. Wallace CJ, Liberman RP, MacKain SJ, Blackwell G, Eckman TA. Effectiveness and replicability of modules for teaching social and instrumental skills to the severely mentally ill. *Am J Psychiatry.* 1992;149(5):654-8.
231. Eckman TA, Liberman RP, Phipps CC, Blair KE. Teaching medication management skills to schizophrenic patients. *J Clin Psychopharmacol.* 1990;10(1):33-8.
232. Rector NA, Beck AT. Cognitive behavioral therapy for schizophrenia: an empirical review. *J Nerv Ment Dis.* 2001;189(5):278-87.
233. Hogarty GE, Greenwald D, Ulrich RF, Kornblith SJ, DiBarry AL, Cooley S, et al. Three-year trials of personal therapy among schizophrenic patients living with or independent of family, II: Effects on adjustment of patients. *Am J Psychiatry.* 1997;154(11):1514-24.
234. Hogarty GE, Kornblith SJ, Greenwald D, DiBarry AL, Cooley S, Ulrich RF, et al. Three-year trials of personal therapy among schizophrenic patients living with or in-

- dependent of family, I: Description of study and effects on relapse rates. *Am J Psychiatry*. 1997;154(11):1504-13.
235. Psychosocial interventions in the management of schizophrenia. A national clinical guideline. Edinburgh (United Kingdom): Scottish Intercollegiate Guidelines Network (SIGN); 1998. SIGN publication núm. 30.
236. Soler Insa PA, Gascón Barrachina J, coordinadores. Recomendaciones terapéuticas en los trastornos mentales (RTM III). Comité de consenso de Catalunya en terapéutica de los trastornos mentales. 3a edición. Barcelona: Ars Medica; 2005.
237. Martens WH. A review of physical and mental health in homeless persons. *Public Health Rev*. 2001;29(1):13-33.
238. Olfson M, Mechanic D, Hansell S, Boyer CA, Walkup J. Prediction of homelessness within three months of discharge among inpatients with schizophrenia. *Psychiatr Serv*. 1999;50(5):667-73.
239. Acute Pain Management Guideline Panel. Acute pain management: operative or medical procedures and trauma. Clinical practice guideline. Rockville, MD (US): Public Health Service. Department of Health and Human Services; 1992.
240. Hospital inpatient management of acute asthma attacks source. Edinburgh (United Kingdom): Scottish Intercollegiate Guidelines Network (SIGN); 1996. Report Number 6.